1American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol, 1994,12(11) :2471.
2Bennett CL, Smith TJ, Weeks JC, et al. Use of hematopoitic colony-stimulating factor: the American Society of Clinical Oncology Surver. J Clin Oncol, 1996,14 (9) : 2511.
3Bensinget WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogenic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood, 1995,85(6) :1655.
5McLeod B C, Sniecinski I, Ciavarella D, et al. Frequency of immediate adverse effects associated with therapeutic apheresis [J]. Transfusion, 1999, 39(3): 282 -288 .
7Roboz GJ.Treatment of acute myeloid leukemia in older patients.Expert Rev Anticancer Ther 2007;7(3):285-295.
8Zubler RH.Ex vivo expansion of hematopoietic stem cells and gene therapy development.Swiss Med Wkly 2006;136(49-50):795-799.
9Kasamon YL.Blood or marrow transplantation for mantle cell lymphoma.Curr Opin Oncol 2007;19(2):128-135.
10Koreth J,Cutler CS,Djulbegovic B,et al.High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:A systematic review and meta-analysis of randomized controlled trials.Biol Blood Marrow Transplant 2007;13(2):183-196.
